Safety and Dosing of Bevacizumab (Avastin) for the Treatment of Recurrent Respiratory Papillomatosis

Objectives: Increasing evidence supports the use of laryngeal injections of the antiangiogenic agent bevacizumab (Avastin) for the adjuvant treatment of recurrent respiratory papillomatosis (RRP). A recent prospective open-label investigation, approved by the US Food and Drug Administration, employi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of otology, rhinology & laryngology rhinology & laryngology, 2012-09, Vol.121 (9), p.587-593
Hauptverfasser:	Best, Simon R., Friedman, Aaron D., Landau-Zemer, Tali, Barbu, Anca M., Burns, James A., Freeman, Mason W., Halvorsen, Yuan-Di, Hillman, Robert E., Zeitels, Steven M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Angiogenesis Angiogenesis Inhibitors - administration & dosage Antibodies, Monoclonal, Humanized - administration & dosage Bevacizumab Biological and medical sciences Blood Combined Modality Therapy Drug dosages Female Humans Immunomodulators Lasers Lasers, Solid-State - therapeutic use Male Medical sciences Middle Aged Otorhinolaryngology. Stomatology Papillomavirus Infections - drug therapy Papillomavirus Infections - surgery Pharmacology. Drug treatments Respiratory Tract Infections - drug therapy Respiratory Tract Infections - surgery Studies
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!